⌕
Kymera Therapeutics · KYMR · Nasdaq
Tenet 41 · Weak
Compare
$121.52−3.44%At closeTenet 41 · Weak
$121.52−4.33 (−3.44%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Kymera Therapeutics (KYMR) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is KYMR's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Seeking AlphaOct 29, 2026 · 14:28 ET
Kymera Therapeutics, Inc. (KYMR) Q3 2026 Earnings Call Transcript

Kymera Therapeutics, Inc. (KYMR) Q3 2026 Earnings Call Transcript…

KYMR −3.4% todayRead at source ↗
● MarketBeatOct 29, 2026 · 14:15 ET
Kymera Therapeutics Q3 Earnings Call Highlights

Kymera Therapeutics NASDAQ: KYMR reported third-quarter results and outlined progress across its clinical pipeline, including phase I healthy-volunteer data for KT-579, an oral degrader targeting IRF5 for autoimmune dise…

KYMR −3.4% todayRead at source ↗
● GlobeNewsWireOct 29, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial

KT-579 (IRF5) Phase 1 healthy volunteer data demonstrated deep, sustained IRF5 degradation, robust modulation of disease-relevant biomarkers and a favorable safety profile…

KYMR −3.4% todayRead at source ↗
● GlobeNewsWireOct 28, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026

WATERTOWN, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological d…

KYMR −3.4% todayRead at source ↗
● GlobeNewsWireOct 22, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026

WATERTOWN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological d…

KYMR −3.4% todayRead at source ↗
● Zacks Investment ResearchOct 19, 2026 · 11:10 ET
Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?

Kymera Therapeutics advances its targeted protein degradation pipeline, with KT-621 trials in atopic dermatitis and asthma marking key milestones amid competition in the field.…

KYMR −3.4% todayRead at source ↗
● PRNewsWireOct 12, 2026 · 09:30 ET
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)

NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Kymera Therapeutics, Inc. (NASDAQ: KYMR) on behalf of the company's shareholders.  The investigation seeks to determine w…

KYMR −3.4% todayRead at source ↗
● PRNewsWireSep 30, 2026 · 08:59 ET
Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm

NEW YORK, Sept. 30, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Kymera Therapeutics, Inc. (NASDAQ: KYMR) breached their fiduciary du…

KYMR −3.4% todayRead at source ↗
● Seeking AlphaSep 15, 2026 · 12:11 ET
Kymera Therapeutics, Inc. (KYMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Kymera Therapeutics, Inc. (KYMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

KYMR −3.4% todayRead at source ↗
● Seeking AlphaSep 10, 2026 · 14:27 ET
Kymera Therapeutics, Inc. (KYMR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Kymera Therapeutics, Inc. (KYMR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript…

KYMR −3.4% todayRead at source ↗
● Zacks Investment ResearchSep 4, 2026 · 12:37 ET
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?

Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock?…

KYMR −3.4% todayRead at source ↗
● Defense WorldSep 4, 2026 · 03:24 ET
Atlas Venture Life Science Advisors LLC Decreases Stock Holdings in Kymera Therapeutics, Inc. $KYMR

Atlas Venture Life Science Advisors LLC lessened its stake in Kymera Therapeutics, Inc. (NASDAQ: KYMR) by 37.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchan…

KYMR −3.4% todayRead at source ↗
● Zacks Investment ResearchSep 3, 2026 · 12:50 ET
Can KT-621 Mark a Turning Point for Kymera Therapeutics?

KYMR advances KT-621 in atopic dermatitis and asthma, with earlier-than-expected AD data and potential phase III plans by mid-2027.…

KYMR −3.4% todayRead at source ↗
● GlobeNewsWireSep 2, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Kymera Therapeutics to Participate in Upcoming September Investor Conferences

WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological …

KYMR −3.4% todayRead at source ↗
● GlobeNewsWireSep 1, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses

Enrollment completed in KT-621 BROADEN2 Phase 2b AD trial with topline data expected by year-end 2026; Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing, with topline data …

KYMR −3.4% todayRead at source ↗
● Defense WorldAug 31, 2026 · 04:21 ET
215,588 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by Bank of New York Mellon Corp

Bank of New York Mellon Corp purchased a new position in shares of Kymera Therapeutics, Inc. (NASDAQ: KYMR) in a recent quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The …

KYMR −3.4% todayRead at source ↗

No upcoming events in the feeds.

NVDA29−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just KYMR · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.